TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16720102

Group type: EXPERIMENTAL
Intervention: Performance Feedback (PF) during MST and SST tests
Number of subjects: 40

Group type: COMPARATOR
Intervention: Modified MST (MSTMD) with auditory feedback
Number of subjects: 40

Group type: COMPARATOR
Intervention: Modified SST (SSTMD) with auditory feedback
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard MST
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard SST
Number of subjects: 40
Study: 15261312

Group type: COMPARATOR
Intervention: Propofol alone
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Propofol plus remifentanil 0.1 microg/kg/min
Number of subjects: 50
Study: 11748380

Group type: EXPERIMENTAL
Intervention: 1 g of red ginseng powder per day for 5 years
Number of subjects: 300
Study: 9624070

Group type: EXPERIMENTAL
Intervention: Hospital at home care
Number of subjects: 241

Group type: COMPARATOR
Intervention: Routine hospital care
Number of subjects: 241
Study: 7946237

Group type: EXPERIMENTAL
Intervention: Enterprise-based sheltered workshops
Number of subjects: 156
Study: 3066849

Group type: EXPERIMENTAL
Intervention: Ganglioside GM1 (100 mg) given daily by intramuscular injection for 28 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29038069

Group type: EXPERIMENTAL
Intervention: Qsymia (phentermine/topiramate ER, 3.75mg/23mg-15mg/92mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 28092792

Group type: EXPERIMENTAL
Intervention: Curiosity
Number of subjects: 117
Study: 24861411

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine (CHX) solution
Number of subjects: 44

Group type: COMPARATOR
Intervention: 0.12% chlorhexidine + 0.05% cetylpyridinium chloride (CPC) solution
Number of subjects: 44
Study: 24171185

Group type: EXPERIMENTAL
Intervention: 20‐min repetitive experimental tooth‐clenching task (50% of maximal voluntary contraction)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control session (no clenching)
Number of subjects: 30
Study: 20724576

Group type: EXPERIMENTAL
Intervention: Rituximab with CHOP-like chemotherapy
Number of subjects: 87

Group type: COMPARATOR
Intervention: CHOP-like chemotherapy without rituximab
Number of subjects: 87
Study: 19764187

Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention including maintenance, protective equipment, procedures, training, health surveillance, fitness for work, first aid
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Health surveillance (HS)
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Safety culture, behaviour and procedures
Number of subjects: 612
Study: 16996347

Group type: EXPERIMENTAL
Intervention: Two bottles of NaP, 12 hours apart
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Two bottles of NaP, 24 hours apart
Number of subjects: 200

Group type: COMPARATOR
Intervention: Two bottles of NaP, 6 hours apart
Number of subjects: 200

Group type: COMPARATOR
Intervention: 4 L PEG
Number of subjects: 200
Study: 15054570

Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP) 0 cm H(2)O
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP) 5 cm H(2)O
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP) 10 cm H(2)O
Number of subjects: 10
Study: 11008905

Group type: EXPERIMENTAL
Intervention: Dysplastic nevi (DN)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Total nevi
Number of subjects: 20

Group type: COMPARATOR
Intervention: Solar injury
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dysplastic nevi (DN) without CDKN2A mutations
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dysplastic nevi (DN) with CDKN2A mutations
Number of subjects: 20
Study: 9278080

Group type: EXPERIMENTAL
Intervention: Active movement of the foot (maximum plantar flexion and dorsiflexion at 30 cycles per minute)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (one minute of rest)
Number of subjects: 38
Study: 7899391

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg + placebo)
Number of subjects: 561

Group type: COMPARATOR
Intervention: Pefloxacin (800 mg + placebo)
Number of subjects: 561
Study: 2693915

Group type: EXPERIMENTAL
Intervention: 2 mg/day of oral micronized E2 (n = 16)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 1.5-3 mg/day of percutaneous E2 (n = 16)
Number of subjects: 32
Study: 302231

Group type: EXPERIMENTAL
Intervention: High power argon laser (6.5 +/- 1.0 w)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Low power argon laser (1.0 +/- 0.1 w)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: High power argon laser (Group B)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Untreated control (Group B)
Number of subjects: 13
Study: 31727335

Group type: EXPERIMENTAL
Intervention: New surgical technique with oval window and stapes reinforcement
Number of subjects: 40

Group type: COMPARATOR
Intervention: Original surgical technique with round window reinforcement
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: New surgical technique
Number of subjects: 40
Study: 30908363

Group type: EXPERIMENTAL
Intervention: Postoperative telephone follow-up (TFU)
Number of subjects: 104

Group type: COMPARATOR
Intervention: No postoperative telephone follow-up (no TFU)
Number of subjects: 104
Study: 28078090

Group type: EXPERIMENTAL
Intervention: Remote physical activity monitoring and feedback (RAMF)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Telephone counselling (TC)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: RAMF
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: TC
Number of subjects: 150
Study: 26466483

Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (ADM) with mixed particles graft
Number of subjects: 67

Group type: COMPARATOR
Intervention: Mixed particles graft (control group)
Number of subjects: 67
Study: 24206747

Group type: EXPERIMENTAL
Intervention: 2 L of PEG3350e with 15 mg bisacodyl
Number of subjects: 325

Group type: COMPARATOR
Intervention: 4 L of PEG3350e
Number of subjects: 325
Study: 22117606

Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg once daily for 4 days starting preoperatively)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (identical capsule)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 20855049

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 48
Study: 17717203

Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (CYC)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 15567545

Group type: EXPERIMENTAL
Intervention: Slower group during sit to stand task
Number of subjects: 41

Group type: COMPARATOR
Intervention: Fast group during sit to stand task
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Slower group
Number of subjects: 41
Study: 12200601

Group type: EXPERIMENTAL
Intervention: Cell-free effusions after exposure in malignant cases
Number of subjects: 123

Group type: COMPARATOR
Intervention: Non-malignant effusions
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: EAL cells in malignant effusions
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: EAL cells in infected effusions
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: sHLA-I levels in malignant effusions
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: sHLA-I levels in infected patients
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: sHLA-I levels in other diseases
Number of subjects: 123
Study: 9704777

Group type: EXPERIMENTAL
Intervention: Relaxin gene expression in tissues from patients with preterm premature rupture of the membranes
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Interleukin-6 gene expression in severely infected tissues
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Interleukin-1beta and interleukin-8 gene expression in severely infected tissues
Number of subjects: 34
Study: 8730886

Group type: EXPERIMENTAL
Intervention: Intrauterine growth restriction (IUGR) group
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 13
Study: 1726988

Group type: EXPERIMENTAL
Intervention: Iloprost (2 ng/kg b.w. per minute for 3 hours)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: OKY‐046 (400 mg single oral dose)
Number of subjects: 24
Study: 7086586

Group type: EXPERIMENTAL
Intervention: Phenylalanine-restricted diet continued
Number of subjects: 115

Group type: COMPARATOR
Intervention: Phenylalanine-restricted diet discontinued
Number of subjects: 115
Study: 31465757

Group type: EXPERIMENTAL
Intervention: Anchor system intervention
Number of subjects: 42

Group type: COMPARATOR
Intervention: No anchor system intervention
Number of subjects: 42

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 42
Study: 30913164

Group type: EXPERIMENTAL
Intervention: mirogabalin 15 mg/day
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: mirogabalin 20 mg/day
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: mirogabalin 30 mg/day
Number of subjects: 765

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 765
Study: 28350787

Group type: EXPERIMENTAL
Intervention: nal-IRI+5-FU/LV
Number of subjects: 236

Group type: COMPARATOR
Intervention: 5-FU/LV
Number of subjects: 236
Study: 25247433

Group type: EXPERIMENTAL
Intervention: Tenofovir gel
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 83
Study: 23558372

Group type: EXPERIMENTAL
Intervention: Injection through a common paraneural sheath
Number of subjects: 89

Group type: COMPARATOR
Intervention: Conventional postbifurcation injection external to the paraneural tissue
Number of subjects: 89
Study: 21499200

Group type: EXPERIMENTAL
Intervention: 75 mg acetylsalicylic acid
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 19730367

Group type: EXPERIMENTAL
Intervention: Binge drinking dose of alcohol
Number of subjects: 428

Group type: COMPARATOR
Intervention: Non-binge drinkers receiving an equivalent dose of alcohol
Number of subjects: 428
Study: 16325937

Group type: EXPERIMENTAL
Intervention: Professional oral care
Number of subjects: 190
Study: 14764947

Group type: EXPERIMENTAL
Intervention: Glucose infusion during ITT
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normal saline (control test)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fructose infusion during ITT
Number of subjects: 8
Study: 11244389

Group type: EXPERIMENTAL
Intervention: Experimental group (n = 10) exposed to dirty glasses
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (n = 10) exposed to neutral slides and objects
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Experimental group (n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 20
Study: 1466329

Group type: EXPERIMENTAL
Intervention: bezafibrate (400 mg/day)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Maxepa (10 g/day)
Number of subjects: 87
Study: 6706275

Group type: EXPERIMENTAL
Intervention: Oral administration of codeine and paracetamol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rectal administration of codeine and paracetamol
Number of subjects: 12
Study: 31690051

Group type: EXPERIMENTAL
Intervention: FiO2 = 0.80
Number of subjects: 0

Group type: COMPARATOR
Intervention: FiO2 = 0.40
Number of subjects: 0
Study: 27933715

Group type: EXPERIMENTAL
Intervention: Retrospective Continuous Glucose Monitoring (CGM)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Self-Monitoring of Blood Glucose (SMBG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control Group (not specified)
Number of subjects: 30
Study: 27940713

Group type: EXPERIMENTAL
Intervention: Food advertisements
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nonfood advertisements (Control)
Number of subjects: 60
Study: 25517808

Group type: EXPERIMENTAL
Intervention: Brief advice about smoking cessation given at the start of anti-tuberculosis treatment, repeated 2 and 5 months later.
Number of subjects: 246

Group type: COMPARATOR
Intervention: Control group with no intervention.
Number of subjects: 246
Study: 22710067

Group type: EXPERIMENTAL
Intervention: Motor training (playing Guitar Hero 2h/day with the nondominant hand)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Immobilization (wearing an immobilization splint 24h/day)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Motor training
Number of subjects: 9

Group type: COMPARATOR
Intervention: Immobilization
Number of subjects: 9
Study: 19326270

Group type: EXPERIMENTAL
Intervention: Brief school-based selective prevention program
Number of subjects: 47

Group type: COMPARATOR
Intervention: Waiting-list control (WLC)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Normal control (NC)
Number of subjects: 47
Study: 18429579

Group type: EXPERIMENTAL
Intervention: Education on rates of live donor kidney transplantation
Number of subjects: 132
Study: 15977735

Group type: EXPERIMENTAL
Intervention: WT-FD filter
Number of subjects: 0
Study: 12870368

Group type: EXPERIMENTAL
Intervention: Telithromycin 800 mg once daily for 5 days
Number of subjects: 376

Group type: COMPARATOR
Intervention: Cefuroxime axetil 500 mg twice daily for 10 days
Number of subjects: 376
Study: 10598299

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tricyclic antidepressants (TCAs)
Number of subjects: 0
Study: 8694150

Group type: COMPARATOR
Intervention: Sodium citrate 0.3 M, 30 ml (group C)
Number of subjects: 384

Group type: COMPARATOR
Intervention: Metoclopramide 10 mg IV + Sodium citrate (group MC)
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Sodium citrate + Ranitidine 50 mg IV (group RC)
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Sodium citrate + Omeprazole 40 mg IV (group OC)
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Sodium citrate + Ranitidine 50 mg + Metoclopramide 10 mg (group RMC)
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Sodium citrate + Omeprazole 40 mg + Metoclopramide 10 mg (group OMC)
Number of subjects: 384

Group type: COMPARATOR
Intervention: Sodium citrate (group C and MC)
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Sodium citrate + Ranitidine, Omeprazole, or Metoclopramide (groups OC, RC, OMC, RMC)
Number of subjects: 384
Study: 1912918

Group type: EXPERIMENTAL
Intervention: Single postprandial test
Number of subjects: 2984

Group type: EXPERIMENTAL
Intervention: Preprandial and postprandial tests
Number of subjects: 2984

Group type: EXPERIMENTAL
Intervention: Screening cost
Number of subjects: 2984

Group type: EXPERIMENTAL
Intervention: Previously undiagnosed diabetes
Number of subjects: 2984
Study: 2868744

Group type: EXPERIMENTAL
Intervention: Bucindolol (50, 100, 200 and 400 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pindolol (10 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bucindolol (200 and 400 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bucindolol (200 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bucindolol (400 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bucindolol
Number of subjects: 12
Study: 29673735

Group type: EXPERIMENTAL
Intervention: Triple drug therapy (TDT) with albendazole (400 mg), pyrantel pamoate (20 mg/kg), and oxantel pamoate
Number of subjects: 414

Group type: COMPARATOR
Intervention: Albendazole plus oxantel pamoate
Number of subjects: 414

Group type: COMPARATOR
Intervention: Pyrantel pamoate plus oxantel pamoate
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Triple drug therapy (TDT) with albendazole, pyrantel pamoate, and oxantel pamoate
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 414
Study: 27378162

Group type: EXPERIMENTAL
Intervention: Large group size (median 8 students)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Standard group size (median 4 students)
Number of subjects: 115
Study: 24275262

Group type: EXPERIMENTAL
Intervention: Barbed sutures
Number of subjects: 34

Group type: COMPARATOR
Intervention: Traditional sutures
Number of subjects: 34
Study: 23984599

Group type: EXPERIMENTAL
Intervention: Functional abdominal pain
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Irritable bowel syndrome
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (healthy children)
Number of subjects: 96
Study: 21653578

Group type: EXPERIMENTAL
Intervention: Implementation intentions linking temptation to dieting goal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 18087270

Group type: EXPERIMENTAL
Intervention: Birth weight <2500 g (exposed)
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: Birth weight >=3860 g (highest quartile)
Number of subjects: 709
Study: 16565792

Group type: EXPERIMENTAL
Intervention: Heparin for 24 hours combined with 325 mg acetyl‐acetic acid (Group A)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 250 mg ticlopidine twice a day combined with 325 mg acetyl‐acetic acid (Group B)
Number of subjects: 100
Study: 12673611

Group type: EXPERIMENTAL
Intervention: Two-session in-home caregiver training program (experimental group, n = 24)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Written educational materials (control group, n = 24)
Number of subjects: 48
Study: 11048358

Group type: EXPERIMENTAL
Intervention: Follow-up rates of 60%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up rates of 90-100%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline characteristics (age)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up rates below 70%
Number of subjects: 0
Study: 8970140

Group type: EXPERIMENTAL
Intervention: 100 mg ferric sodium citrate
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 100 mg ferric sodium citrate with 200 mg ascorbic acid
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 100 mg ferric sodium citrate with physical exercise
Number of subjects: 8

Group type: COMPARATOR
Intervention: 100 mg ferric sodium citrate without vitamin C
Number of subjects: 8
Study: 1468743

Group type: EXPERIMENTAL
Intervention: Oral bacterial lysate
Number of subjects: 620
Study: 6204149

Group type: EXPERIMENTAL
Intervention: Slow release potassium tablets (64 mmol/day)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Slow release potassium tablets (98 mmol/day)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 31434466

Group type: EXPERIMENTAL
Intervention: Elevated central venous pressure (CVP)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Elevated airway pressure
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Accumulated fluid balance
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Elevated SOFA score
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Reduction of acidosis
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Increase of serum bicarbonate
Number of subjects: 25
Study: 29924507

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate once-monthly (PP1M)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 27371719

Group type: EXPERIMENTAL
Intervention: Perindopril 10 mg
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 224

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study: 25453520

Group type: EXPERIMENTAL
Intervention: Footbath at 41°C for 15 minutes
Number of subjects: 22
Study: 22670846

Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 132

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 132
Study: 20619139

Group type: EXPERIMENTAL
Intervention: Moxibustion
Number of subjects: 65

Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 65
Study: 17293760

Group type: EXPERIMENTAL
Intervention: Team-centered curriculum
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: One-on-one motivational interviewing (MI)
Number of subjects: 599

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 599
Study: 15585567

Group type: EXPERIMENTAL
Intervention: Propranolol (beta-adrenergic blocker)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Metyrapone (corticosteroid synthesis inhibitor)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 12013162

Group type: EXPERIMENTAL
Intervention: 22-item questionnaire
Number of subjects: 630
Study: 10468758

Group type: EXPERIMENTAL
Intervention: Absorbable (polyglyconate) staples
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nonabsorbable (metal) staples
Number of subjects: 50
Study: 7782111

Group type: EXPERIMENTAL
Intervention: Roxithromycin
Number of subjects: 242

Group type: COMPARATOR
Intervention: Amoxycillin/clavulanic acid
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of Roxithromycin
Number of subjects: 242
Study: 2351709

Group type: EXPERIMENTAL
Intervention: Dydrogesterone three times daily (TID) beginning on the day of embryo transfer (ET)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: HCG on days 3, 6 and 10 following ET
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo p.o. TID beginning on the day of ET
Number of subjects: 156
Study: 400187

Group type: EXPERIMENTAL
Intervention: Post-operative radiotherapy
Number of subjects: 650

Group type: COMPARATOR
Intervention: Chemotherapy, immunotherapy, immunochemotherapy, and observation
Number of subjects: 650
Study: 31682584

Group type: EXPERIMENTAL
Intervention: Smartphone-based approach-avoidance intervention (n=35)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo control group (n=35)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Inactive control group (n=35)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: All groups (experimental, placebo, inactive)
Number of subjects: 105
Study: 29306231

Group type: EXPERIMENTAL
Intervention: Local autograft with allograft
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Local autograft only
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Local autograft and posterior iliac crest autograft
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 65